YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[The NASDAQ Stock Exchange headquarters in New York, USA] JHVEPhoto/iStock Editorial via Getty Images Nasdaq (NASDAQ:NDAQ [https://seekingalpha.com/symbol/NDAQ]) on Wednesday announced [https://seekingalpha.com/pr/20242487-delisting-of-sec…
PHILADELPHIA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alto Neuroscience, Inc. (NYSE: ANRO): Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). The investigation concerns whether certain…
Earnings Call Insights: Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 MANAGEMENT VIEW * Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our planned Phase IIIb clinical trial." The ENDURANCE…
* BrainStorm Cell Therapeutics press release [https://seekingalpha.com/pr/20200769-brainstorm-cell-therapeutics-announces-second-quarter-2025-financial-results-and-provides] (OTC:BCLI [https://seekingalpha.com/symbol/BCLI]): Q2 GAAP EPS of…
Major earnings expected before the bell on Thursday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Deere & Company (DE [https://seekingalpha.com/symbol/DE]) * First Majestic Silver Corp. (AG [https://seekingalpha.com/symbol/…
* BrainStorm Cell Therapeutics (OTC:BCLI [https://seekingalpha.com/symbol/BCLI]) is scheduled to announce Q2 earnings results on Thursday, August 14th, before market open. * The consensus EPS Estimate is -$0.33 [https://seekingalpha.com/sy…
NEW YORK - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), currently valued at $11.56 million in market capitalization, will be delisted from the Nasdaq Capital Market effective Thursday, with trading suspended at market open, the company…
* BrainStorm Cell Therapeutics (NASDAQ:BCLI [https://seekingalpha.com/symbol/BCLI]) filed to sell 2.76M shares of common stock for holders. * This prospectus is not an offer to sell. * Filing [https://seekingalpha.com/filing/10128008] MORE…
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainsto…
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsu…
LOS ANGELES, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or…
BENSALEM, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, bo…
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly…
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainsto…
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or…
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BC…
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, bo…
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of invest…
LOS ANGELES, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsu…
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainsto…
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310)…
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, bo…
BENSALEM, Pa., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
LOS ANGELES, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or…
LOS ANGELES, Nov. 16, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsu…
NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, bo…
NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of invest…
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310)…
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainsto…
NEW YORK, Nov. 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, bo…
LOS ANGELES, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310)…